Bringing over 20 years of experience as a senior leader in the pharmaceutical industry, most recently as Vice President of Genentech Research and Early Development, Greg is currently the Owner and Principal of Cosma Biopharma Consulting, LLC. Greg is currently a member of the Scientific Advisory Board of Immune-Onc Therapeutics and the R&D Advisory Board of Erasca, Inc. Greg has led efforts across R&D that have resulted in numerous approvals of currently marketed drugs, spanning diverse therapeutic areas and modalities. In addition to his broad development responsibilities at Genentech, Greg led Project Agility, an organization-wide effort to enhance innovation and pipeline delivery. He is widely considered as a trusted and transformative thought leader in the industry, applying disruptive strategies to enhance and accelerate pipeline delivery and efficiency. Prior to his career in biopharma, Greg was a faculty member at New York University Medical Center and Colorado State University.